1. Home
  2. DEVS vs CTXR Comparison

DEVS vs CTXR Comparison

Compare DEVS & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DEVS
  • CTXR
  • Stock Information
  • Founded
  • DEVS N/A
  • CTXR 2007
  • Country
  • DEVS Canada
  • CTXR United States
  • Employees
  • DEVS N/A
  • CTXR N/A
  • Industry
  • DEVS
  • CTXR Biotechnology: Pharmaceutical Preparations
  • Sector
  • DEVS
  • CTXR Health Care
  • Exchange
  • DEVS NYSE
  • CTXR Nasdaq
  • Market Cap
  • DEVS 14.6M
  • CTXR 14.6M
  • IPO Year
  • DEVS N/A
  • CTXR N/A
  • Fundamental
  • Price
  • DEVS $0.39
  • CTXR $1.53
  • Analyst Decision
  • DEVS
  • CTXR Strong Buy
  • Analyst Count
  • DEVS 0
  • CTXR 3
  • Target Price
  • DEVS N/A
  • CTXR $53.00
  • AVG Volume (30 Days)
  • DEVS 1.1M
  • CTXR 6.7M
  • Earning Date
  • DEVS 07-07-2025
  • CTXR 08-11-2025
  • Dividend Yield
  • DEVS N/A
  • CTXR N/A
  • EPS Growth
  • DEVS N/A
  • CTXR N/A
  • EPS
  • DEVS N/A
  • CTXR N/A
  • Revenue
  • DEVS $10,164.00
  • CTXR N/A
  • Revenue This Year
  • DEVS N/A
  • CTXR N/A
  • Revenue Next Year
  • DEVS N/A
  • CTXR N/A
  • P/E Ratio
  • DEVS N/A
  • CTXR N/A
  • Revenue Growth
  • DEVS N/A
  • CTXR N/A
  • 52 Week Low
  • DEVS $0.18
  • CTXR $0.65
  • 52 Week High
  • DEVS $3.00
  • CTXR $26.25
  • Technical
  • Relative Strength Index (RSI)
  • DEVS N/A
  • CTXR 68.44
  • Support Level
  • DEVS N/A
  • CTXR $0.76
  • Resistance Level
  • DEVS N/A
  • CTXR $1.45
  • Average True Range (ATR)
  • DEVS 0.00
  • CTXR 0.31
  • MACD
  • DEVS 0.00
  • CTXR 0.06
  • Stochastic Oscillator
  • DEVS 0.00
  • CTXR 47.63

About DEVS DEVVSTREAM CORP

DevvStream Corp is a technology-based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve its sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Share on Social Networks: